This scenario suggests that targeting CAFs activation and/or recruitment at iCCA tumor sites may offer new therapeutic strategies and potential therapeutic benefits for controlling iCCA aggressiveness caused by activated CAFs. Here, TBX1 is linked to neoplasm.